• DOI:10.1093/bja/aet308
• Corpus ID: 21227746

Capsaicin 8% patch for treprostinil subcutaneous infusion site pain in pulmonary hypertension patients.

@article{Libri2014Capsaicin8P,
  title={Capsaicin 8\% patch for treprostinil subcutaneous infusion site pain in pulmonary hypertension patients.},
  author={Vincenzo Libri and J. Simon R. Gibbs and D J Pinato and T. Iddamalgoda and Rajeshree H. Khengar and Wendy Gin-Sing and L. W. Huson and Pushpa Rani Anand},
  journal={British journal of anaesthesia},
  year={2014},
  volume={112 2},
  pages={
          337-47
        }
}

• V. Libri, J. Gibbs, +5 authors P. Anand
• Published 1 February 2014
• Medicine
• British journal of anaesthesia

BACKGROUND
Treprostinil sodium improves haemodynamics and symptoms in pulmonary arterial hypertension (PAH) patients, but its subcutaneous (s.c.) administration can produce severe local site pain, and lead to discontinuation of vital treatment. Treprostinil is a prostacyclin analogue which stimulates prostacyclin receptors in skin nociceptor terminals, resulting in pain and cutaneous hypersensitivity, for which current pain remedies have limited effect. Capsaicin 8% patch relieves neuropathic pain for 3 months after a single 60 min cutaneous application; we investigated whether its pre-application can reduce s.c. trepostinil-induced pain.

METHODS
A single-centre, double-blind, randomized, placebo-controlled, crossover study was conducted to assess the safety and efficacy of a single capsaicin 8% patch pre-application for s.c. treprostinil pain in 11 PAH patients, relative to control patch with low-dose capsaicin 0.075% cream.

RESULTS
The primary efficacy endpoint, mean difference between the two treatment arms in an 11-point numerical pain rating scale from baseline to 2 weeks after patch applications, was significantly lower on the capsaicin 8% patch treatment arm [P=0.01, mean difference=-1.47 units, 95% credible interval (CI): -2. 59 to -0.38] in the patients who completed the study per protocol, although intention-to-treat analysis did not show significant difference (P=0.28). Heat pain thresholds were decreased (P=0.027, mean difference=5.43°C, 95% CI: 0.71-10.21) and laser Doppler flux increased (P=0.016, mean difference=370 units, 95% CI: 612 to 127.9) at the application site immediately after capsaicin 8% patch, confirming activity.

CONCLUSIONS
Further investigation of the efficacy of capsaicin 8% patch in this indication is warranted.